Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revumenib - Syndax Pharmaceuticals

Next Previous
Drug Profile

Revumenib - Syndax Pharmaceuticals

Alternative Names: Revumenib; SNDX-5613

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Syndax Pharmaceuticals
  • Class Antineoplastics; Aza compounds; Benzamides; Cyclohexanes; Pyrimidines; Small molecules; Spiro compounds; Sulfonamides
  • Mechanism of Action Menin inhibitors; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase II Acute biphenotypic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Colorectal cancer; Solid tumours

Most Recent Events

  • 15 Apr 2024 Syndax Pharmaceuticals has US and non-US patents pending for Revumenib in USA and Europe
  • 15 Apr 2024 Syndax Pharmaceuticals has US and non-US patents granted for Revumenib in USA and Europe
  • 10 Apr 2024 Updated efficacy and adverse events data from a phase I/II AUGMENT-101 trial released by Syndax Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top